The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

The U.S. Health and Human Services Department says it will require placebo testing of "all new vaccines," raising questions ...